Hormonal Influences on Cognition and Risk for Alzheimer’s Disease
- 529 Downloads
Research increasingly suggests that changes in estrogen levels during aging may increase the risk of Alzheimer’s disease, the most common type of dementia. This update reviews the newest information about estrogen and cognitive aging, including information regarding the role of bioavailable estrogen in older women and men, use of selective estrogen receptor modulators to improve cognition, and studies of genetic risk factors to elucidate the effects of endogenous estrogen on aging and cognition. Future trials are needed to determine whether alternate timing, dosage, formulation, or method of administration of hormone replacement can reduce the risk of dementia.
KeywordsAlzheimer’s Disease Dementia Estrogen Hormone Replacement Therapy Genetics
Dr. Janicki receives support from the Charles L. and Ann Lee Saunders Brown Fellowship fund and National Institutes of Health (NIH) grant 5 T32 MH2004 Clinical Research Training in Geriatric Neuropsychiatry.
Dr. Schupf receives support from NIH grants #R01AG014673 (principal investigator [PI]), #P01HD035897 (coinvestigator [Co-I]), #P01AG07232 (Co-I), #R01AG028786 (Co-I), #U01 AG023749 (Co-I), #P50 AG08702 (Co-I), #R01AG007370 (Co-I), #R21CA125461 (Co-I), #R01AG036040 (Co-I), and #AG034189 (Co-I) and from Alzheimer’s Association grants #IIRG-08-90655 (PI) and #IIRG-08-92010 (Co-I).
Dr. Schupf is a consultant to Janssen Alzheimer Immunotherapy. No other potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 20.• Henderson VW: Aging, estrogens and episodic memory in women. Cogn Behav Neurol 2009, 22:205–214. This is a useful review of the relationships between estrogen exposure and memory in women, with a discussion of the critical-window hypothesis in estrogen supplementation. CrossRefPubMedGoogle Scholar
- 22.Joffe H, Hall JE, Gruber S, et al.: Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause 2006, 13:411–422.CrossRefPubMedGoogle Scholar
- 27.Wolf OT, Kudielka BM, Hellhammer DH, et al.: Two weeks of transdermal estradiol treatment in postmenopausal elderly women and its effect on memory and mood: verbal memory changes are associated with the treatment induced estradiol levels. Psychoneuroendocrinology 1999, 24:727–741.CrossRefPubMedGoogle Scholar
- 29.Linzmayer L, Semlitsch HV, Saletu B, et al.: Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. Arzneimittelforschung 2001, 51:238–245.PubMedGoogle Scholar
- 37.• Sano M, Jacobs D, Andrews H, et al.: A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics. Clin Trials 2008, 5:523–533. This article describes the design of the PREPARE trial. Although the study results are not yet published, it is anticipated they will address whether there are lasting or delayed effects of HRT on cognition after treatment cessation. CrossRefPubMedGoogle Scholar
- 38.•• Miller VM, Black DM, Brinton EA, et al.: Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009, 2:228–239. This article discusses the design and rationale of KEEPS, which will investigate the critical-timing hypothesis of estrogen supplementation by evaluating the effects of HRT on a younger female population. CrossRefPubMedGoogle Scholar
- 39.Early vs Late Intervention Trial with Estradiol (ELITE). Available at http://clinicaltrials.gov/ct2/show/NCT00114517. Accessed March 2010.
- 62.Sherwin BB, Chertkow H, Schipper H, Nasreddine Z: A randomized controlled trial of estrogen treatment in men with mild cognitive impairment. Neurobiol Aging (Epub ahead of print). Google Scholar
- 66.•• Espeland MA, Shumaker SA, Limacher M, et al.: Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. J Womens Health (Larchmt) 2010, 19:371–379. This secondary analysis study raises the possibility that both tamoxifen and raloxifene adversely affect cognitive function in older women; however, the magnitude of the effect is small and the long-term consequences are unknown.CrossRefGoogle Scholar
- 74.• Yaffe K, Lindquist K, Sen S, et al.: Estrogen receptor genotype and risk of cognitive impairment in elders: findings from the Health ABC study. Neurobiol Aging 2009, 30:607–614. This study’s findings that several SNPs in the ESR1 and ESR2 genes were associated with risk of developing cognitive impairment suggest that ER genetic variants might play a role in cognitive aging.CrossRefPubMedGoogle Scholar